Savara (SVRA) Receivables (2016)
Savara (SVRA) posted quarterly Receivables of $400000.0 for Q4 2016.
Savara (SVRA) Receivables (2016) Analysis & Trends
Savara (SVRA) has reported Receivables for 1 consecutive years, with $400000.0 the latest figure, recorded in Q4 2016.
- In Q4 2016, Receivables changed N/A year-over-year to $400000.0; the TTM figure through Dec 2016 stood at $400000.0 (changed N/A YoY), while the FY2016 annual figure was $400000.0, changed N/A from the prior year.
- Receivables held at $400000.0 in Q4 2016 per SVRA's latest filing.
- Across five years, Receivables topped out at $400000.0 in Q4 2016 and bottomed at $400000.0 in Q4 2016.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.93 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.06 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1.84 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 912.74 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 215.33 Mn |
| 10 | Savara | 1.11 Bn | 1.11 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2016 | 400,000.00 |